5VA Stock Chart & Stats
€48.80
-€0.20(-0.41%)
At close: 4:00 PM EDT
€48.80
-€0.20(-0.41%)
Day’s Range― - ―
52-Week Range€24.80 - €52.00
Previous CloseN/A
Volume0.00
Average Volume (3M)55.00
Market Cap
€7.98B
Enterprise Value€7.03K
Total Cash (Recent Filing)€1.49B
Total Debt (Recent Filing)€115.44M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 09, 2026EPS Estimate
-1.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.64
Shares Outstanding148,805,280
10 Day Avg. Volume52
30 Day Avg. Volume55
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.82Price Target Upside100.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Large Equity BaseA very low debt-to-equity ratio and a sizable equity cushion provide durable financial flexibility for a pre-commercial biotech. This reduces near-term liquidity risk and gives management structural optionality to fund clinical programs, strategic partnerships, or manufacturing scale-up without immediate refinancing pressure.
Phase 3 Programs Fully Enrolled With BLA PathFully enrolled pivotal trials and an explicit timetable for topline readouts create a clear, durable development pathway toward a Biologics License Application. If results are favorable, this materially changes the company’s long-term revenue prospects and reduces binary development risk by advancing regulatory readiness and manufacturing consistency work.
CSP Platform Targeting Broader Serotype CoverageThe carrier-sparing polysaccharide platform targets a structural competitive advantage: broader serotype coverage versus incumbent conjugate vaccines. Platform-driven breadth can create durable differentiation across markets (infant and adult) and support multiple product candidates, improving long-term commercial optionality if clinical success is achieved.
Bears Say
Accelerating Negative Operating Cash FlowRapidly increasing cash consumption is a durable risk: sustained negative operating cash flow of this magnitude requires repeated external financing, which can dilute shareholders and constrain strategic choices. Persistent high burn rates raise execution risk if capital markets tighten or clinical timelines slip.
Pre-commercial Status With No Product RevenueAbsence of commercial revenues is a structural limitation: without product sales the company relies on financing, partnerships, or milestones to fund operations. Continued widening losses increase dependency on external capital and heighten the consequences of adverse clinical/regulatory outcomes for long-term viability.
Negative Returns On EquitySubstantially negative ROE signals capital erosion rather than value creation, a durable investor concern. Over time, persistent negative returns indicate that R&D and spending have yet to translate to asset productivity, increasing the bar for future clinical success to justify continued capital deployment.
Vaxcyte News
5VA FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was €24.80 and its highest was €52.00 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is €7.98B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 77 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Aug 05, 2026. The company reported -€1.706 earnings per share for the quarter, beating the consensus estimate of -€1.781 by €0.074.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.84.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 148,805,280 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -€1.706 in its last earnings report, beating expectations of -€1.781. Following the earnings report the stock price went down -3.347%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in DE:5VA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€97.82 (100.46% Upside)
€97.82 (100.46% Upside)
Blogger Sentiment
Bullish
DE:5VA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.06%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
5VA Stock 12 Month Forecast
Average Price Target
€97.82
▲(100.46% Upside)